Last reviewed · How we verify
Formoterol stada
Formoterol stada is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by Fundacio Privada Mon Clinic Barcelona. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: LABA.
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Formoterol stada |
|---|---|
| Also known as | LABA |
| Sponsor | Fundacio Privada Mon Clinic Barcelona |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. Its long-acting formulation provides symptom control and airway opening for 12 hours or more, making it suitable for maintenance therapy in chronic obstructive airway diseases.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- ANTES B+ Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Formoterol stada CI brief — competitive landscape report
- Formoterol stada updates RSS · CI watch RSS
- Fundacio Privada Mon Clinic Barcelona portfolio CI
Frequently asked questions about Formoterol stada
What is Formoterol stada?
How does Formoterol stada work?
What is Formoterol stada used for?
Who makes Formoterol stada?
Is Formoterol stada also known as anything else?
What drug class is Formoterol stada in?
What development phase is Formoterol stada in?
What are the side effects of Formoterol stada?
What does Formoterol stada target?
Related
- Drug class: All Long-acting beta-2 agonist (LABA) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor
- Manufacturer: Fundacio Privada Mon Clinic Barcelona — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Also known as: LABA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing